

I. AMENDMENTS

In the specification:

Please amend the paragraph beginning at line 26 on page 9 as follows:

G 1  
--The devices are those materials which are generally approved for use as implants in the body or could be so approved. They may be of polymers such as polyethylene, polyacrylics, polypropylene, polyvinylchloride, polyamides such as Nylon, polyurethanes, polyvinylpyrrolidone, polyvinyl alcohols, polyvinylacetate, cellulose acetate, polystyrene, polytetrafluoroethylene, polyesters such as polyethylene terephthalate (DACRON™), silk, cotton, and the like. When the polymers are fibrous, they are often looped or tufted. Although it is not critical to this invention, they are usually assembled in bundles of 5 to 100 fibers per bundle. Preferred materials for the polymer component of vaso-occlusive devices comprise polyesters, polyethers, polyamides, and polyfluorocarbons. Especially preferred is polyethyleneterephthalate, sold as DACRON™.--

In the claims:

GB 1  
G 2  
1. (Amended) A vaso-occlusive composition comprising a vaso-occlusive member and a material selected from the group consisting of liquid fibrin; polyethylene glycol derivatives; thrombin-coated gelatin granules; balloons coated with iron microspheres, trace metals, thrombus-stabilizing molecules and combinations thereof.

G 3  
21. (Amended) The method of claim 20, wherein the cytokine is selected from the group consisting of PDGF,  $\beta$ FGF, VEGF and TGF-beta.

Please add new claims 31 to 36 as follows:

G 4  
31. (New) A vaso-occlusive composition a vaso-occlusive member and a particulate liquid embolic material.